Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Not yet recruiting 3Active not recruiting 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 1

Interventions

pembrolizumab 74Cyclophosphamide 50Cisplatin 46Nivolumab 36Radiotherapy 33Paclitaxel 33Carboplatin 31Gemcitabine 30Docetaxel 27Dexamethasone 24atezolizumab 23Doxorubicin 21Bevacizumab 21Etoposide 20Blood Specimen Collection 20Vincristine 18Magnetic Resonance Spectroscopy 18Leucovorin 18Lenalidomide 18Fluorouracil 18fludarabine 17Rituximab 17Radiosurgery 17Surveys and Questionnaires 16Oxaliplatin 16Cytarabine 16Radiation 15Ipilimumab 15palbociclib 14durvalumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × axatilimab × 90 days × Clear all
NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
5 enrolled 13 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡